

Prion protein (PrP) deposits in the tectum of experimental Gerstmann-Sträussler-Scheinker disease following intraocular inoculation

Pawel P. Liberski¹, Johannes A. Hainfellner², Beata Sikorska¹, Herbert Budka²

¹Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland, ²Institute of Neurology, University of Vienna, Vienna, Austria

Folia Neuropathol 2012; 50 (1): 85-88

Abstract

The abnormal misfolded isoform of prion protein (PrP^d; “d” for disease) is considered as a surrogate marker for infectivity in the transmissible spongiform encephalopathies (TSEs) or prion diseases, including Creutzfeldt-Jakob disease (CJD). In this experiment, we used intraocular inoculation to study PrP^d deposition in the visual system of the brain of mice infected with the Fujisaki (K.Fu) strain of Gerstmann-Sträussler-Scheinker (GSS) disease. We report here that PrP^d is deposited in the superior colliculus following contralateral intraocular inoculation and thus follows neuronal connections when it spreads into the brain. Until 26 weeks postinoculation, no PrP^d-specific immunostaining was observed in the brain. At 27 weeks postinoculation, PrP^d targeted to the contralateral superior colliculus as delicate granular synaptic deposits located in the superficial part of this structure. As already reported, a few spongiform vacuoles were visible in the same area by conventional H&E staining. In several other sections, vacuoles were visible but no PrP^d staining could be detected.

Key words: prion, prion diseases, Gerstmann-Sträussler-Scheinker disease, spreading of prions.

Introduction

The abnormal misfolded isoform of prion protein (PrP^d; “d” for disease) is considered as a surrogate marker for infectivity in the transmissible spongiform encephalopathies (TSEs) or prion diseases [30], including Creutzfeldt-Jakob disease (CJD) [3,6,31]. In this experiment, we used intraocular inoculation to study PrP^d deposition in the visual system of the brain of mice infected with the Fujisaki (K.Fu) strain of Gerstmann-

Sträussler-Scheinker (GSS) disease. We report here that PrP^d is deposited in the superior colliculus following contralateral intraocular inoculation and thus follows neuronal connections when it spreads into the brain [32].

Material and methods

The experiment was designed to recapitulate that of targeting scrapie pathology to the contralateral superior colliculus following intraocular injection [32]. To this

Communicating author:

Pawel P. Liberski, Department of Molecular Pathology and Neuropathology, Chair of Oncology, Medical University of Lodz, 8/10 Czechoslowacka st., 92-216 Lodz, Poland, phone/fax: +48 42 679 14 77, e-mail: pplibers@csk.umed.lodz.pl




Fig. 1. Low (A) and high (B) magnification of expression of PrP (arrows) in superior colliculus 27th week postinoculation.




Fig. 2. The same region stained with H&E.

end, four- to five-week-old NIH Swiss mice of both sexes were inoculated into the right anterior eye chamber with 0.01 mL of a 10% (w/v) clarified brain suspension of the Fujisaki strain of GSS [33,34]. Brains were collected beginning at 18 weeks postinoculation and the experiment was terminated when unequivocal

spongiform changes appeared in the contralateral superior colliculus. The latter part of the experiment has been already published [32]. Two mice were sacrificed weekly by decapitation under light anaesthesia with ketamine and brains were immediately fixed in 10% buffered formalin. Brains were then transected coronally to include the mesencephalon with superior colliculi and lateral geniculate bodies. For immunohistochemistry, paraffin-embedded sections were immersed in 100% formic acid for 15 minutes, then equilibrated in digestion buffer (50 mM TRIS-HCL, 1 mM ethylenediaminetetraacetic acid, 0.1% Tween 20, pH 7.8) for 5 minutes and treated with proteinase K (1 µg/mL in digestion buffer) for 15 minutes at 37°C followed by autoclaving in distilled water for 15 minutes (121°C) in a pressure cooker. We used the 6H4 monoclonal anti-PrP antibody (Prionics, Zurich) or 3F4 antibody (DAKO) and the ABC technique with the Vectastatin Elite ABC-kit, using DAB as chromogen as previously described [27].

Results

Until 26 weeks postinoculation, no PrP^d-specific immunostaining was observed in the brain. At 27 weeks postinoculation, PrP^d targeted to the contralateral superior colliculus as delicate granular synaptic deposits located in the superficial part of this structure (Fig. 1A-B). As already reported [32] (Fig. 2), a few spongiform vacuoles were visible in the same area by conventional H&E staining. In several other sections, vacuoles were visible but no PrP^d staining could be detected.

Discussion

The involvement of the visual system is well recognised in prion diseases. First, if scrapie is inoculated intraocularly, infection travels along the optic nerves to target the superior colliculi and lateral geniculate bodies [16-18,24,25,32,37-40]. Second, scrapie replicates in the eye [11,23] and PrP^d is expressed in the retina [12] and its mRNA is detected in the optic tectum [19]. In variant CJD, PrP^d is expressed in the retina and the proximal part of the optic nerve at levels of 2.5% and 25% of the brain concentration, respectively [20,43]. Third, the retina degenerates in several models of scrapie and CJD in rodents as a result of apoptosis of ganglion cells [7-10,14,15,21,23], and cases of CJD and GSS with retinal or geniculate body degeneration or optic nerve atrophy have already been reported [1,2,26,29,36,41,42]. Of note, in a GSS case with bila-

teral optic atrophy, the retina was normal [41]. Fourth, iatrogenic CJD cases following corneal transplantation have been described [4].

Here, we report that following intraocular inoculation, both spongiform change and PrP deposition targeted the superior colliculus as it has been showed by classical neuropathologic methods [32]. This targeting of PrP to the superior colliculus showed that PrP^d and spongiform change follow structured neural pathways of the visual system of the brain, as already suggested in studies on the spread of infectivity from the periphery to the central nervous system [32]. Of note, spongiform change in the superior colliculus was not always accompanied by PrP deposition, and this discrepancy has also been noticed, albeit infrequently, by other investigators [28]. Alterations in the glycosylation pattern have been studied following inoculation into the superior colliculus in two models (the ME7 and the 139A) of scrapie in rodents [35]. The non-glycosylated PrP band increased first in the retina and then in the optic nerves while the deglycosylated band decreased concomitantly. Thus, alterations of the glycosylation pattern follows the structure of the optic pathways – these changes appear first in the cell bodies and then in their respective axons. These data, along with our immunohistochemical studies, strongly suggest spreading of infectivity and its surrogate marker PrP^d through connections of the visual system via fast axonal transport [5]. Indeed, the mutation at the first glycosylation site results in the accumulation of PrP^d within the cell bodies [13].

Acknowledgements

This study, supported in part by an Austrian-Polish research agreement (awarded to both Prof. Herbert Budka and Prof. Pawel P. Liberski), is a part of EC “Neuro-Prion” Network of Excellence.

References

1. Aguglia U, Gambarelli D, Farnarier G, Quattrone A. Different susceptibilities of the geniculate and extrageniculate visual pathways to human Creutzfeldt-Jakob disease (a combined neurophysiological-neuropathological study). *Electroencephalogr Clin Neurophysiol* 1991; 78: 413-423.
2. Aoki T, Kobayashi K, Jibiki I, Muramori F, Hayashi M, Miyazu K, Kobayashi E, Koshino Y, Yamaguchi N. An autopsied case of Creutzfeldt-Jakob disease with the lateral geniculate body lesion showing antagonizing correlation between periodic synchronous discharges and photically induced giant evoked responses. *Psychiatry Clin Neurosci* 1998; 52: 333-337.
3. Armstrong RA. Dispersion of prion protein deposits around blood vessels in variant Creutzfeldt-Jakob disease. *Folia Neuropathol* 2010; 48: 150-158.
4. Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, Gajdusek DC, Gibbs CJ Jr. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. *Lancet* 1977; 1: 478-479.
5. Borchelt DR, Koliatsos VE, Guarnieri M, Pardo CA, Sisodia SS, Price DL. Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. *J Biol Chem* 1994; 269: 14711-14714.
6. Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Jellinger K, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). *Brain Pathol* 1995; 5: 459-466.
7. Buyukmihci N, Goehring-Harmon F, Marsh RF. Asymmetry of retinal lesions in experimental scrapie after intracerebral inoculation of hamsters. *Exp Neurol* 1985; 87: 172-176.
8. Buyukmihci N, Goehring-Harmon F, Marsh RF. Neural pathogenesis of experimental scrapie after intraocular inoculation of hamsters. *Exp Neurol* 1983; 81: 396-406.
9. Buyukmihci N, Goehring-Harmon F, Marsh RF. Retinal degeneration in experimental scrapie after intraperitoneal or subcutaneous inoculation of hamsters. *Exp Neurol* 1985; 88: 461-466.
10. Buyukmihci N, Marsh RF, Albert DM, Zelinski K. Ocular effects of scrapie agent in hamsters: preliminary observations. *Invest Ophthalmol Vis Sci* 1977; 16: 319-324.
11. Buyukmihci N, Rorvik M, Marsh RF. Replication of the scrapie agent in ocular neural tissues. *Proc Natl Acad Sci U S A* 1980; 77: 1169-1171.
12. Chishti MA, Strome R, Carlson GA, Westaway D. Syrian hamster prion protein (PrP(C)) is expressed in photoreceptor cells of the adult retina. *Neurosci Lett* 1997; 234: 11-14.
13. DeArmond SJ, Sánchez H, Yehiely F, Qiu Y, Ninchak-Casey A, Daggett V, Camerino AP, Cayetano J, Rogers M, Groth D, Torchia M, Tremblay P, Scott MR, Cohen FE, Prusiner SB. Selective neuronal targeting in prion disease. *Neuron* 1997; 19: 1337-1348.
14. Foster JD, Davies DJ, Fraser H. Primary retinopathy in scrapie in mice deprived of light. *Neurosci Lett* 1986; 72: 111-114.
15. Foster JD, Fraser H, Bruce ME. Retinopathy in mice with experimental scrapie. *Neuropathol Appl Neurobiol* 1986; 12: 185-196.
16. Foster JD, Scott JR, Fraser H. The use of monosodium glutamate in identifying neuronal populations in mice infected with scrapie. *Neuropathol Appl Neurobiol* 1990; 16: 423-430.
17. Fraser H. Neuronal spread of scrapie agent and targeting of lesions within the retino-tectal pathway. *Nature* 1982; 295: 149-150.
18. Fraser H, Dickinson AG. Targeting of scrapie lesions and spread of agent via retino-tectal projection. *Brain Res* 1985; 346: 32-41.
19. Harris DA, Lele P, Snider WD. Localization of the mRNA for a chicken prion protein by in situ hybridization. *Proc Natl Acad Sci U S A* 1993; 90: 4309-4313.
20. Head MW, Northcott V, Rennison K, Ritchie D, McCauley L, Bunn TJ, McLennan NF, Ironside JW, Tullo AB, Bonshek RE. Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. *Invest Ophthalmol Vis Sci* 2003; 44: 342-346.

21. Hogan RN, Baringer JR, Prusiner SB. Progressive retinal degeneration in scrapie-infected hamsters: a light and electron microscopic analysis. *Lab Invest* 1981; 44: 34-42.
22. Hogan RN, Bowman KA, Baringer JR, Prusiner SB. Replication of scrapie prions in hamster eyes precedes retinal degeneration. *Ophthalmic Res* 1986; 18: 230-235.
23. Hogan RN, Kingsbury DT, Baringer JR, Prusiner SB. Retinal degeneration in experimental Creutzfeldt-Jakob disease. *Lab Invest* 1983; 49: 708-715.
24. Jeffrey M, Fraser JR, Halliday WG, Fowler N, Goodsir CM, Brown DA. Early unsuspected neuron and axon terminal loss in scrapie-infected mice revealed by morphometry and immunocytochemistry. *Neuropathol Appl Neurobiol* 1995; 21: 41-49.
25. Kimberlin RH, Walker CA. Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly. *J Gen Virol* 1986; 67: 255-263.
26. Kitagawa Y, Gotoh F, Koto A, Ebihara S, Okayasu H, Ishii T, Matsuyama H. Creutzfeldt-Jakob disease: a case with extensive white matter degeneration and optic atrophy. *J Neurol* 1983; 229: 97-101.
27. Kordek R, Hainfellner JA, Liberski PP, Budka H. Deposition of the prion protein (PrP) during the evolution of experimental Creutzfeldt-Jakob disease. *Acta Neuropathol* 1999; 98: 597-602.
28. Lasmézas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Hauw JJ, Rossier J, Dormont D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. *Science* 1997; 275: 402-405.
29. Lesser RL, Albert DM, Bobowick AR, O'Brien FH. Creutzfeldt-Jakob disease and optic atrophy. *Am J Ophthalmol* 1979; 87: 317-321.
30. Liberski PP, Kuru and D. Carleton Gajdusek: a close encounter. *Folia Neuropathol* 2009; 47: 114-137.
31. Liberski PP. Prion diseases: a riddle wrapped in a mystery inside an enigma. *Folia Neuropathol* 2008; 46: 93-116.
32. Liberski PP, Yanagihara R, Gibbs CJ Jr, Gajdusek DC. Spread of Creutzfeldt-Jakob disease virus along visual pathways after intraocular inoculation. *Arch Virol* 1990; 111: 141-147.
33. Liberski PP, Yanagihara R, Gibbs CJ Jr, Gajdusek DC. Appearance of tubulovesicular structures in experimental Creutzfeldt-Jakob disease and scrapie precedes the onset of clinical disease. *Acta Neuropathol* 1990; 79: 349-354.
34. Liberski PP, Yanagihara R, Gibbs CJ Jr, Gajdusek DC. White matter ultrastructural pathology of experimental Creutzfeldt-Jakob disease in mice. *Acta Neuropathol* 1989; 79: 1-9.
35. Russelakis-Carneiro M, Saborio GP, Anderes L, Soto C. Changes in the glycosylation pattern of prion protein in murine scrapie. Implications for the mechanism of neurodegeneration in prion diseases. *J Biol Chem* 2002; 277: 36872-36877.
36. Sato Y, Chiba S, Miyagishi T. A case of the panencephalopathic type of Creutzfeldt-Jakob disease with retinal involvement. *Hokkaido Igaku Zasshi* 1992; 67: 703-711 [Japanese].
37. Scott JR, Fraser H. Enucleation after intraocular scrapie injection delays the spread of infection. *Brain Res* 1989; 504: 301-305.
38. Scott JR, Fraser H. Transport and targeting of scrapie infectivity and pathology in the optic nerve projections following intraocular infection. *Prog Clin Biol Res* 1989; 317: 645-652.
39. Scott JR, Davies D, Fraser H. Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. *J Gen Virol* 1992; 73: 1637-1644.
40. Scott JR, Reekie LJ, Hope J. Evidence for intrinsic control of scrapie pathogenesis in the murine visual system. *Neurosci Lett* 1991; 133: 141-144.
41. Sugai F, Nakamori M, Nakatsuji Y, Abe K, Sakoda S. A case of Gerstmann-Sträussler-Scheinker syndrome (P102L) accompanied by optic atrophy. *Rinsho Shinkeigaku* 2000; 40: 926-928 [Japanese].
42. Tsutsui J, Kawashima S, Kajikawa I, Shirabe T, Terao A. Electrophysiological and pathological studies on Creutzfeldt-Jakob disease with retinal involvement. *Doc Ophthalmol* 1986; 63: 13-21.
43. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge J. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. *Lancet* 2001; 358: 171-180.